μ3 Opiate receptor expression in lung and lung carcinoma: Ligand binding and coupling to nitric oxide release

C. Fimiani; E. Arcuri; A. Santoni; C. M. Rialas; T. V. Bilfinger; D. Peter; B. Salzet; G. B. Stefano

doi:10.1016/S0304-3835(99)00227-X

μ3 Opiate receptor expression in lung and lung carcinoma: Ligand binding and coupling to nitric oxide release

C. Fimiani
, E. Arcuri
, A. Santoni
, C. M. Rialas
, T. V. Bilfinger
, D. Peter
, B. Salzet
, G. B. Stefano

Surgery

Stony Brook University

SUNY Old Westbury
University of Rome La Sapienza
IRCCS Istituti fisioterapici ospitalieri - Istituto Regina Elena
Centre de Biologie Cellulaire
Stony Brook University

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Abstract

The μ3 opiate receptor subtype is expressed in human surgical specimens of both normal lung and non-small-cell lung carcinoma. Nitric oxide (NO) release is mediated through the μ3 receptor, and in lung carcinoma, morphine-stimulated NO release is significantly higher and prolonged than in normal lung. Using reverse transcriptase-polymerase chain reaction (RT-PCR) and Southern blot analysis we show that specific μ opioid receptor transcripts are present in lung carcinoma and other cells with the μ3 profile. Our findings identify a unique role for the μ3 opiate receptor in opiate-mediated NO release and suggest that endogenous opiates, through their release of NO, may play a role in cancer progression. Copyright (C) 1999 Elsevier Science Ireland Ltd.

Original language	English
Pages (from-to)	45-51
Number of pages	7
Journal	Cancer Letters
Volume	146
Issue number	1
DOIs	https://doi.org/10.1016/S0304-3835(99)00227-X
State	Published - Nov 1 1999

Keywords

Alternative splicing
Cancer
Lung
Morphine
Neoplasia
Nitric oxide
Opioid receptor transcript
μ

Access to Document

10.1016/S0304-3835(99)00227-X

Cite this

@article{72ec07ffa9234bcfb3293638f8dcd09b,

title = "μ3 Opiate receptor expression in lung and lung carcinoma: Ligand binding and coupling to nitric oxide release",

abstract = "The μ3 opiate receptor subtype is expressed in human surgical specimens of both normal lung and non-small-cell lung carcinoma. Nitric oxide (NO) release is mediated through the μ3 receptor, and in lung carcinoma, morphine-stimulated NO release is significantly higher and prolonged than in normal lung. Using reverse transcriptase-polymerase chain reaction (RT-PCR) and Southern blot analysis we show that specific μ opioid receptor transcripts are present in lung carcinoma and other cells with the μ3 profile. Our findings identify a unique role for the μ3 opiate receptor in opiate-mediated NO release and suggest that endogenous opiates, through their release of NO, may play a role in cancer progression. Copyright (C) 1999 Elsevier Science Ireland Ltd.",

keywords = "Alternative splicing, Cancer, Lung, Morphine, Neoplasia, Nitric oxide, Opioid receptor transcript, μ",

author = "C. Fimiani and E. Arcuri and A. Santoni and Rialas, \{C. M.\} and Bilfinger, \{T. V.\} and D. Peter and B. Salzet and Stefano, \{G. B.\}",

year = "1999",

month = nov,

day = "1",

doi = "10.1016/S0304-3835(99)00227-X",

language = "English",

volume = "146",

pages = "45--51",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - μ3 Opiate receptor expression in lung and lung carcinoma

T2 - Ligand binding and coupling to nitric oxide release

AU - Fimiani, C.

AU - Arcuri, E.

AU - Santoni, A.

AU - Rialas, C. M.

AU - Bilfinger, T. V.

AU - Peter, D.

AU - Salzet, B.

AU - Stefano, G. B.

PY - 1999/11/1

Y1 - 1999/11/1

N2 - The μ3 opiate receptor subtype is expressed in human surgical specimens of both normal lung and non-small-cell lung carcinoma. Nitric oxide (NO) release is mediated through the μ3 receptor, and in lung carcinoma, morphine-stimulated NO release is significantly higher and prolonged than in normal lung. Using reverse transcriptase-polymerase chain reaction (RT-PCR) and Southern blot analysis we show that specific μ opioid receptor transcripts are present in lung carcinoma and other cells with the μ3 profile. Our findings identify a unique role for the μ3 opiate receptor in opiate-mediated NO release and suggest that endogenous opiates, through their release of NO, may play a role in cancer progression. Copyright (C) 1999 Elsevier Science Ireland Ltd.

AB - The μ3 opiate receptor subtype is expressed in human surgical specimens of both normal lung and non-small-cell lung carcinoma. Nitric oxide (NO) release is mediated through the μ3 receptor, and in lung carcinoma, morphine-stimulated NO release is significantly higher and prolonged than in normal lung. Using reverse transcriptase-polymerase chain reaction (RT-PCR) and Southern blot analysis we show that specific μ opioid receptor transcripts are present in lung carcinoma and other cells with the μ3 profile. Our findings identify a unique role for the μ3 opiate receptor in opiate-mediated NO release and suggest that endogenous opiates, through their release of NO, may play a role in cancer progression. Copyright (C) 1999 Elsevier Science Ireland Ltd.

KW - Alternative splicing

KW - Cancer

KW - Lung

KW - Morphine

KW - Neoplasia

KW - Nitric oxide

KW - Opioid receptor transcript

KW - μ

UR - https://www.scopus.com/pages/publications/0032585763

U2 - 10.1016/S0304-3835(99)00227-X

DO - 10.1016/S0304-3835(99)00227-X

M3 - Article

C2 - 10656608

SN - 0304-3835

VL - 146

SP - 45

EP - 51

JO - Cancer Letters

JF - Cancer Letters

IS - 1

ER -

μ3 Opiate receptor expression in lung and lung carcinoma: Ligand binding and coupling to nitric oxide release

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this